Humanities
Skip to main content Skip to main navigation menu Skip to site footer
  • Register
  • Login
  • Menu
  • Home
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Register
  • Login

Journal of Education, Health and Sport

Irritable bowel syndrome – modern ways of treatment
  • Home
  • /
  • Irritable bowel syndrome – modern ways of treatment
  1. Home /
  2. Archives /
  3. Vol. 16 No. 1 (2023) /
  4. Articles

Irritable bowel syndrome – modern ways of treatment

Authors

  • Jakub Kuciński Medical University of Warsaw https://orcid.org/0000-0002-1331-8339
  • Zuzanna Fryska Uniwersytecki Szpital Kliniczny in Poznań, Poznan University of Medical Sciences https://orcid.org/0000-0002-8055-2897
  • Adam Wołejko Wielospecjalistyczny Szpital Miejski im. Józefa Strusia z Zakładem Opiekuńczo Leczniczym in Poznań https://orcid.org/0000-0002-1815-8370
  • Kacper Kulik Wojewódzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego SPZOZ in Lublin https://orcid.org/0000-0003-3829-5740
  • Paweł Semeniuk Wojewódzki Szpital Chirurgii Urazowej św. Anny SPZOZ in Warszawa https://orcid.org/0009-0009-7250-9483
  • Krystian Matusz Zakład Anatomii Prawidłowej Uniwersytetu Medycznego im. Karola Marcinkowskiego in Poznań https://orcid.org/0000-0003-2668-1556
  • Rafał Burczyk Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz https://orcid.org/0000-0002-1650-1534
  • Natalie Górna https://orcid.org/0000-0001-8588-3241

DOI:

https://doi.org/10.12775/JEHS.2023.16.01.005

Keywords

Irritable bowel syndrome, constipation, gastrointestinal motility, brain-gut axis, intestinal secretion

Abstract

Introduction

Irritable bowel syndrome (IBS) is the most frequent functional disorder of the gastrointestinal tract.  Main symptoms are recurring stomach ache connected with defecation, changes of frequency of defecation and/or stool’s consistency. Cause of IBS is still unknown unlike its pathomechanism. Continuous research allows doctors to understand and treat it better.

Discussion

Diagnosing IBS might be difficult even for the most experienced doctors due to its uncharacteristic symptoms. Therefore diagnosis should be made by using Rome IV Criteria. IBS is divided into 4 subtypes  basing on clinical picture: IBS with predominant constipation, IBS with predominant diarrhea, IBS with mixed bowel habits and IBS unclassified. Classification is being performed with the use of Bristol Stool Chart. Choice of remedy should be made depending on the subtype of IBS. Pharmacological treatment is symptomatic and focuses on relieving pain, diarrhea, constipation and bloating. Drugs that can be used are: loperamide, rifaximin, antispasmodic (e.g. hyoscine), antidepressants or laxatives. Treatment should also contain nonpharmacological methods. Nonpharmacological techniques which are proved to help patients contain regular physical activity, body mass reduction, low-FODMAP diet, using probiotics, psychotherapy and supplementing soluble fibre.

Conclusions

IBS is a big issue for public health as it is lowering quality of life and is generating big indirect costs. Difficulties in diagnosing are increasing those costs. That’s why it is of high importance to find more effective therapy. Raising awareness among doctors is crucial as plenty of methods are available to treat the disease which allows to reduce symptoms and costs.

References

Tang YR, Yang WW, Liang ML, Xu XY, Wang MF, Lin L. Age-related symptom and life quality changes in women with irritable bowel syndrome. World J Gastroenterol WJG. 2012 Dec 28;18(48):7175–83.

Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016 Feb 19;S0016-5085(16)00223-7.

Weber HC. Irritable bowel syndrome and diet. Curr Opin Endocrinol Diabetes Obes. 2022 Apr;29(2):200–6.

Cashman MD, Martin DK, Dhillon S, Puli SR. Irritable Bowel Syndrome: A Clinical Review. Curr Rheumatol Rev. 2016;12(1):13–26.

Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014 Dec;6:71–80.

Gwee K a. Irritable bowel syndrome in developing countries – a disorder of civilization or colonization? Neurogastroenterol Motil. 2005;17(3):317–24.

Stachowska E, Maciejewska D, Ryterska K, Baszuk P, Żydecka KS, Rogowska MC, et al. Abdominal Pain and Disturbed Bowel Movements are Frequent among Young People. A Population Based Study in Young Participants of the Woodstock Rock Festival in Poland. J Gastrointestin Liver Dis. 2018 Dec;27(4):379–83.

Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: A multivariable analysis. Gastroenterology. 2004 Jun;126(7):1665–73.

Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications? Gastroenterology. 2002 Apr;122(4):1140–56.

Adrych K, Rydzewska G. Rozpoznawanie i leczenie zespołu jelita nadwrażliwego w praktyce lekarza rodzinnego. Forum Med Rodz. 2019;13(6):269–78. Polish

Pietrzak A, Skrzydło-Radomańska B, Mulak A, Lipiński M, Małecka-Panas E, Reguła J, et al. Guidelines on the management of irritable bowel syndrome. Gastroenterol Rev. 2018;13(4):259–88.

Staudacher HM, Lomer MCE, Farquharson FM, Louis P, Fava F, Franciosi E, et al. A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial. Gastroenterology. 2017 Oct;153(4):936–47.

Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel Disorders. Gastroenterology. 2016 Feb;S0016-5085(16)00222-5.

Adrych K. Zespół jelita drażliwego w świetle najnowszych wytycznych. Forum Med Rodz [Internet].2018 Polish [cited 2023 Mar 3];12(6). Available from: https://journals.viamedica.pl/forum_medycyny_rodzinnej/article/view/61827

Spiegel BMR, Bolus R, Agarwal N, Sayuk G, Harris LA, Lucak S, et al. Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials. Aliment Pharmacol Ther. 2010 Nov;32(10):1275–91.

Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021 Jul;70(7):1214–40.

Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015 Mar;110(3):444–54.

Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess Winch Engl. 2013 Nov;17(55):xv–xix, 1–211.

Moayyedi P, Mearin F, Azpiroz F, Andresen V, Barbara G, Corsetti M, et al. Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. United Eur Gastroenterol J. 2017 Oct;5(6):773–88.

Chen B, Kim JJW, Zhang Y, Du L, Dai N. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol. 2018 Jul;53(7):807–18.

Black TP, Manolakis CS, Palma JAD. “Red Flag” Evaluation Yield in Irritable Bowel Syndrome. J Gastrointestin Liver Dis. 2012 Jun;21(2):153–6.

Palsson OS, Baggish J, Whitehead WE. Episodic nature of symptoms in irritable bowel syndrome. Am J Gastroenterol. 2014 Sep;109(9):1450–60.

Adriani A, Ribaldone DG, Astegiano M, Durazzo M, Saracco GM, Pellicano R. Irritable bowel syndrome: the clinical approach. Panminerva Med. 2018 Dec;60(4):213–22.

Johannesson E, Simrén M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011 May;106(5):915–22.

Schneck AS, Anty R, Tran A, Hastier A, Amor IB, Gugenheim J, et al. Increased Prevalence of Irritable Bowel Syndrome in a Cohort of French Morbidly Obese Patients Candidate for Bariatric Surgery. Obes Surg. 2016 Jul;26(7):1525–30.

Aasbrenn M, Lydersen S, Farup PG. A Conservative Weight Loss Intervention Relieves Bowel Symptoms in Morbidly Obese Subjects with Irritable Bowel Syndrome: A Prospective Cohort Study. J Obes. 2018;2018:3732753.

Hajizadeh Maleki B, Tartibian B, Mooren FC, FitzGerald LZ, Krüger K, Chehrazi M, et al. Low-to-moderate intensity aerobic exercise training modulates irritable bowel syndrome through antioxidative and inflammatory mechanisms in women: Results of a randomized controlled trial. Cytokine. 2018 Feb;102:18–25.

Liu J, Chey WD, Haller E, Eswaran S. Low-FODMAP Diet for Irritable Bowel Syndrome: What We Know and What We Have Yet to Learn. Annu Rev Med. 2020 Jan;71:303–14.

Camilleri M. Management Options for Irritable Bowel Syndrome. Mayo Clin Proc. 2018 Dec;93(12):1858–72.

Simon E, Călinoiu LF, Mitrea L, Vodnar DC. Probiotics, Prebiotics, and Synbiotics: Implications and Beneficial Effects against Irritable Bowel Syndrome. Nutrients. 2021 Jun;13(6):2112.

Shahbazkhani B, Sadeghi A, Malekzadeh R, Khatavi F, Etemadi M, Kalantri E, et al. Non-Celiac Gluten Sensitivity Has Narrowed the Spectrum of Irritable Bowel Syndrome: A Double-Blind Randomized Placebo-Controlled Trial. Nutrients. 2015 Jun;7(6):4542–54.

Jacobs JP, Gupta A, Bhatt RR, Brawer J, Gao K, Tillisch K, et al. Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome. 2021 Nov;9(1):236.

Baboș CI, Leucuța DC, Dumitrașcu DL. Meditation and Irritable Bowel Syndrome, a Systematic Review and Meta-Analysis. J Clin Med. 2022 Jan;11(21):6516.

Lysko M, Baszczyńska P. Zespół jelita drażliwego – aktualne zasady postępowania. Farmacja Polska.2019;75(1):8-11; Polish

Ford AC, Moayyedi P, Chey WD, Harris LA, Lacy BE, Saito YA, et al. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2018 Jun;113(Suppl 2):1–18.

Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013 Aug;145(2):329-338.e1.

Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012 Jan;107(1):28–35; quiz 36.

Camilleri M, Ford AC. Pharmacotherapy for Irritable Bowel Syndrome. J Clin Med. 2017 Oct;6(11):101.

Abdul-Baki H, El Hajj II, Elzahabi L, Azar C, Aoun E, Skoury A, et al. A randomized controlled trial of imipramine in patients with irritable bowel syndrome. World J Gastroenterol. 2009 Aug;15(29):3636–42.

Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S, Jones M. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci. 2008 Jan;53(1):108–15.

Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut. 2011 Feb;60(2):209–18.

Sarosiek I, Bashashati M, Alvarez A, Hall M, Shankar N, Gomez Y, et al. Lubiprostone Accelerates Intestinal Transit and Alleviates Small Intestinal Bacterial Overgrowth in Patients With Chronic Constipation. Am J Med Sci. 2016 Sep;352(3):231–8.

Busby RW, Bryant AP, Bartolini WP, Cordero EA, Hannig G, Kessler MM, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol. 2010 Dec;649(1–3):328–35.

Chang WCL, Masih S, Thadi A, Patwa V, Joshi A, Cooper HS, et al. Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc+/Min-FCCC mice. World J Gastrointest Pharmacol Ther. 2017 Feb;8(1):47–59.

Fielding JF. Double blind trial of trimebutine in the irritable bowel syndrome. Ir Med J. 1980 Oct;73(10):377–9.

Hou X, Chen S, Zhang Y, Sha W, Yu X, Elsawah H, et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014 Nov;34(11):783–93.

Banasiewicz T, Borycka-Kiciak K, Dobrowolska-Zachwieja A, Friediger J, Kiciak A, Krokowicz P, et al. Clinical aspects of sodium butyrate application in dietary treatment of bowel diseases. Gastroenterol Rev. 2010;6:329–34.

Treem WR, Ahsan N, Kastoff G, Hyams JS. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. J Pediatr Gastroenterol Nutr. 1996 Oct;23(3):280–6.

Cuche G, Blat S, Malbert CH. Desensitization of ileal vagal receptors by short-chain fatty acids in pigs. Am J Physiol Gastrointest Liver Physiol. 2001 May;280(5):G1013-1021.

Soret R, Chevalier J, De Coppet P, Poupeau G, Derkinderen P, Segain JP, et al. Short-chain fatty acids regulate the enteric neurons and control gastrointestinal motility in rats. Gastroenterology. 2010 May;138(5):1772–82.

Downloads

  • PDF

Published

2023-03-21

How to Cite

1.
KUCIŃSKI, Jakub, FRYSKA, Zuzanna, WOŁEJKO, Adam, KULIK, Kacper, SEMENIUK, Paweł, MATUSZ, Krystian, BURCZYK, Rafał and GÓRNA, Natalie. Irritable bowel syndrome – modern ways of treatment. Journal of Education, Health and Sport. Online. 21 March 2023. Vol. 16, no. 1, pp. 40-48. [Accessed 27 December 2025]. DOI 10.12775/JEHS.2023.16.01.005.
  • ISO 690
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 16 No. 1 (2023)

Section

Articles

License

Copyright (c) 2023 Jakub Kuciński, Zuzanna Fryska, Adam Wołejko, Kacper Kulik, Paweł Semeniuk, Krystian Matusz, Rafał Burczyk, Natalie Górna

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 1090
Number of citations: 0

Search

Search

Browse

  • Browse Author Index
  • Issue archive

User

User

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians

Newsletter

Subscribe Unsubscribe

Tags

Search using one of provided tags:

Irritable bowel syndrome, constipation, gastrointestinal motility, brain-gut axis, intestinal secretion
Up

Akademicka Platforma Czasopism

Najlepsze czasopisma naukowe i akademickie w jednym miejscu

apcz.umk.pl

Partners

  • Akademia Ignatianum w Krakowie
  • Akademickie Towarzystwo Andragogiczne
  • Fundacja Copernicus na rzecz Rozwoju Badań Naukowych
  • Instytut Historii im. Tadeusza Manteuffla Polskiej Akademii Nauk
  • Instytut Kultur Śródziemnomorskich i Orientalnych PAN
  • Instytut Tomistyczny
  • Karmelitański Instytut Duchowości w Krakowie
  • Ministerstwo Kultury i Dziedzictwa Narodowego
  • Państwowa Akademia Nauk Stosowanych w Krośnie
  • Państwowa Akademia Nauk Stosowanych we Włocławku
  • Państwowa Wyższa Szkoła Zawodowa im. Stanisława Pigonia w Krośnie
  • Polska Fundacja Przemysłu Kosmicznego
  • Polskie Towarzystwo Ekonomiczne
  • Polskie Towarzystwo Ludoznawcze
  • Towarzystwo Miłośników Torunia
  • Towarzystwo Naukowe w Toruniu
  • Uniwersytet im. Adama Mickiewicza w Poznaniu
  • Uniwersytet Komisji Edukacji Narodowej w Krakowie
  • Uniwersytet Mikołaja Kopernika
  • Uniwersytet w Białymstoku
  • Uniwersytet Warszawski
  • Wojewódzka Biblioteka Publiczna - Książnica Kopernikańska
  • Wyższe Seminarium Duchowne w Pelplinie / Wydawnictwo Diecezjalne „Bernardinum" w Pelplinie

© 2021- Nicolaus Copernicus University Accessibility statement Shop